Anti - Mouse, MSH2 Clone FE11
- Known as:
- Anti - Mouse, MSH2 Clone FE11
- Catalog number:
- 60-0046-7
- Product Quantity:
- 7mL
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- Anti - Mouse MSH2 Clone FE11
Related genes to: Anti - Mouse, MSH2 Clone FE11
- Gene:
- MSH2 NIH gene
- Name:
- mutS homolog 2
- Previous symbol:
- COCA1
- Synonyms:
- HNPCC, HNPCC1
- Chromosome:
- 2p21-p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-07-28
- Date modifiied:
- 2019-04-23
Related products to: Anti - Mouse, MSH2 Clone FE11
Related articles to: Anti - Mouse, MSH2 Clone FE11
- - Source: PubMed
Publication date: 2026/08/25
Moisoiu VladLourman RoxanneSzulzewsky FrankKessler TobiasCollotta GiulioPorro AntonioBertolini AnneSinger FranziskaCimino Patrick JHertler CarolineWick WolfgangReifenberger GuidoHolland Eric CSartori Alessandro AWeller MichaelWirsching Hans-Georg - Sebaceous adenoma is a rare benign sebaceous neoplasm that only exceptionally involves the ocular adnexa. Caruncular lesions are particularly uncommon and often resemble more frequently encountered lesions such as papilloma. Correct diagnosis of these tumours is important because sebaceous neoplasms may be associated with Muir-Torre syndrome (MTS), a hereditary cancer predisposition syndrome within the Lynch syndrome spectrum. Modern pathology reports incorporate mismatch repair (MMR) immunohistochemistry to help identify patients who may require genetic assessment and cancer surveillance. We present the case of an 81-year-old woman who presented with a right caruncular lesion associated with epiphora and mucoid discharge. Clinical examination demonstrated a cream coloured papillomatous lesion that was mobile and not adherent to adjacent structures. The lesion was presumed clinically to represent a benign papilloma and was excised during combined lacrimal surgery. Histopathological examination demonstrated a well-circumscribed lobulated sebaceous proliferation composed predominantly of mature sebocytes with peripheral basaloid germinative cells and no significant atypia, consistent with sebaceous adenoma. Immunohistochemistry demonstrated preserved nuclear expression of MutL Homologue 1 (MLH1), postmeiotic segregation increased 2 (PMS2), MutS homologue 2 (MSH2) and MutS homologue 6 (MSH6), indicating intact MMR function and reducing suspicion for MTS. Sebaceous adenoma should be considered in the differential diagnosis of cream-white papillomatous caruncular lesions. Ophthalmologists should understand the significance of MMR immunohistochemistry, as abnormal results may identify patients requiring genetic referral, whereas preserved expression is generally reassuring and supports a sporadic lesion. Retained nuclear staining for MLH1, PMS2, MSH2 and MSH6 indicated preserved MMR function (MMR proficient; pMMR), which predicts microsatellite stability (MSS). In conjunction with the patient's age and absence of a personal history of malignancy, these findings strongly favoured a sporadic sebaceous adenoma. Although intact MMR expression does not completely exclude MTS, abnormal staining would have prompted consideration of genetic referral and systemic evaluation. Our report expands upon previous literature by providing a practical explanation of MMR immunohistochemistry aimed at ophthalmologists, who may be the first clinicians to recognise sebaceous neoplasia and initiate appropriate MTS screening. - Source: PubMed
Publication date: 2026/07/22
Cheung ImogenCheung David - Deficiency in SWItch/Sucrose Non-FermenTable (SWI/SNF) related barrier-to-autointegration factor (BAF) chromatin remodeling complex subunit ATPase 4 (SMARCA4) drives aggressive behavior across various undifferentiated malignancies. However, its clinicopathological features, prognostic analysis, and molecular significance in undifferentiated digestive system malignancies, clinically rare and poorly characterized entities, remain incompletely elucidated. This study investigated the clinicopathological characteristics and prognostic significance of a retrospective cohort (n = 43). Immunohistochemistry (IHC) identified SMARCA4 deficiency in 30.2% of undifferentiated malignant tumors of the digestive system. Clinically, SMARCA4 deficiency constituted a significant poor-prognosis predictor, correlating with poorer overall survival [OS; hazard ratio (HR) = 3.054, 95% confidence interval (CI) 1.277-7.306, log-rank p = 0.006] and disease-free survival (DFS; HR = 2.717, 95% CI 1.129-6.539, log-rank p = 0.015), independent of assessed lineage markers or microsatellite status. Integrated analysis of The Cancer Genome Atlas (TCGA) data of digestive system malignancies revealed that SMARCA4-mutated tumors exhibited elevated tumor mutational burden (TMB) and distinct co-mutation patterns. Notably, SMARCA4 mutations significantly co-occurred with multiple potentially actionable therapeutic targets, including receptor tyrosine kinases (ERBB2, ERBB3, MET, and RET), DNA damage response genes (BRCA2), and mismatch repair genes (MLH1, MSH2, MSH6). Collectively, our findings identified SMARCA4 deficiency as a predictor of poor prognoses in digestive system malignancies, suggesting a distinct genomic context that may inform therapeutic stratification, including targeted and immunotherapeutic approaches, by focusing on these high-frequency co-mutated targets. © 2026 The Pathological Society of Great Britain and Ireland. - Source: PubMed
Publication date: 2026/08/20
Guo Yun-RanLiu ChangBai XiaoLi Ke-ChenZhao Jia-BaoLin KunZhao Zi-TingLang Ji-XuanLi Xiao-HanWu Qi-JunZhang Chun-Dong - Colorectal cancer (CRC) is a major public health burden in Hainan Province due to its high incidence and mortality, yet region-specific prognostic data are lacking. This study evaluates prognostic factors in postsurgical CRC patients to guide localized prevention and treatment. - Source: PubMed
Du LeSun LuyaoGe DongshengWang MingfaYu BenguoYang WenjunYang WenlongAn RuyuanLi JunchaoZhu JikeWang ZaipanLiu NingCao Wenting - DNA mismatch repair (MMR) deficiency is a clinically important biomarker in human oncology, yet its relevance in feline neoplasia remains poorly understood due to limited characterisation and the absence of validated reagents. In this study, we established a practical immunohistochemistry (IHC) approach for evaluating feline MMR proteins by confirming the cross-reactivity of anti-human MLH1, MSH2 and MSH6 antibodies using CRISPR/Cas9-engineered feline tumour cell lines lacking each target gene. Using these validated antibodies, we conducted a pilot screening to assess MMR protein expression in 83 feline tumours and observed variable reductions or losses of MLH1, MSH2 and MSH6 across several tumour types. Notably, MLH1 expression was lost in all melanoma cases (6/6, 100%) and in most osteosarcomas (14/15, 93%), indicating that MMR perturbations may be particularly relevant in these malignancies. These findings provide the first analytically validated framework for assessing MMR proteins in feline oncology and suggest that MMR dysregulation may be more widespread than previously recognised. Although the clinical sample size is limited, this initial pilot screening maps the preliminary landscape of feline MMR protein expression. Further large-scale validation studies incorporating microsatellite instability testing, methylation analysis and genomic profiling are warranted to clarify the biological significance of these alterations. - Source: PubMed
Publication date: 2026/08/16
Nishibori ShomaSakurai MasashiKagawa YumikoNishigaki KazuoNakagawa TakayukiInanaga SakuyaIgase MasayaMizuno Takuya